1. Introduction and Background
Cathelicidins constitute a family of host defence peptides found across vertebrate species, characterised by a conserved cathelin-like prosequence domain and a structurally variable C-terminal antimicrobial domain. In humans, the cathelicidin family is represented by a single member: the 37-amino-acid peptide LL-37, so named for the two leucine residues at its N-terminus. LL-37 is derived from the proteolytic cleavage of the 18 kDa precursor protein hCAP-18 (human cationic antimicrobial protein 18), which is encoded by the CAMP gene located on chromosome 3 (Zanetti, 2004). The precursor is constitutively expressed in neutrophil specific granules, where it represents one of the most abundant antimicrobial proteins, and is additionally expressed by epithelial cells of the skin, respiratory tract, gastrointestinal tract, and urogenital system upon induction by inflammatory stimuli or vitamin D receptor activation (Dürr, Sudheendra and Ramamoorthy, 2006).
The biological significance of LL-37 extends substantially beyond direct microbial killing. Over the past two decades, a considerable body of research has established that LL-37 functions as a multifunctional effector molecule of the innate immune system, capable of modulating inflammatory responses, promoting chemotaxis of immune cells, influencing wound repair processes, and neutralising bacterial endotoxin. This breadth of activity has positioned LL-37 as a molecule of substantial interest in immunological and antimicrobial research, with potential implications for understanding host defence mechanisms in infection, chronic wounds, and inflammatory conditions (Vandamme et al., 2012).
2. Structure and Biophysical Properties
LL-37 adopts an amphipathic alpha-helical conformation in membrane-mimetic environments, a structural feature that is central to its biological activities. The peptide carries a net positive charge of +6 at physiological pH, arising from the presence of multiple lysine and arginine residues distributed along its sequence. This cationic character, combined with the amphipathic helical architecture that segregates hydrophobic and hydrophilic residues to opposing faces of the helix, enables preferential interaction with negatively charged microbial membranes over the zwitterionic phospholipid composition of mammalian cell surfaces (Dürr, Sudheendra and Ramamoorthy, 2006).
Biophysical studies have demonstrated that the helical structure of LL-37 is solvent-dependent. In aqueous solution, the peptide exists in a largely unstructured or random coil conformation, transitioning to the alpha-helical state upon interaction with lipid bilayers, detergent micelles, or at elevated peptide concentrations that promote oligomerisation. This conformational plasticity is thought to be functionally important, permitting the peptide to remain soluble in biological fluids while adopting the membrane-active helical form upon encountering target membranes (Wang, 2014).
3. Mechanism of Action: Membrane Disruption and Immunomodulation
3.1 Membrane-Disruptive Antimicrobial Activity
The primary antimicrobial mechanism attributed to LL-37 involves direct physical disruption of microbial cell membranes. The cationic amphipathic peptide is electrostatically attracted to the anionic lipopolysaccharide (LPS) of Gram-negative bacteria or the lipoteichoic acid and peptidoglycan of Gram-positive organisms. Upon binding, LL-37 inserts into the lipid bilayer, where accumulation of peptide molecules leads to membrane permeabilisation through mechanisms that may include toroidal pore formation, carpet-like membrane dissolution, or detergent-like micellisation of the lipid bilayer (Hancock and Sahl, 2006). The resulting loss of membrane integrity leads to dissipation of the transmembrane electrochemical gradient, leakage of cytoplasmic contents, and ultimately microbial cell death.
Importantly, LL-37 has also been demonstrated to interact with intracellular targets following membrane translocation. At sub-inhibitory concentrations, the peptide can traverse bacterial membranes without causing immediate lysis and interfere with intracellular processes including DNA and RNA synthesis, protein folding, and cell wall biosynthesis. This multi-target mode of action is considered a significant advantage relative to conventional antibiotics that typically engage a single molecular target, as it substantially reduces the probability of resistance emergence (Wang, 2014).
3.2 Immunomodulatory Signalling
Beyond its direct antimicrobial effects, LL-37 exerts a complex array of immunomodulatory activities that collectively serve to orchestrate the innate immune response. Scott et al. (2002) demonstrated that LL-37 modulates the expression of inflammatory genes in macrophages, selectively upregulating certain chemokines while suppressing the pro-inflammatory signalling induced by bacterial lipopolysaccharide. Specifically, LL-37 was shown to inhibit LPS-induced TNF-α production while simultaneously enhancing the expression of chemokines involved in immune cell recruitment, suggesting that the peptide functions to redirect rather than simply suppress the inflammatory response (Scott et al., 2002).
This capacity for selective immune modulation is mechanistically attributed to the ability of LL-37 to bind and neutralise LPS, thereby preventing its interaction with Toll-like receptor 4 (TLR4), while simultaneously activating alternative signalling pathways through direct engagement of host cell receptors. The peptide has been reported to signal through multiple receptor systems, including the formyl peptide receptor-like 1 (FPRL1/FPR2), the purinergic receptor P2X7, and the epidermal growth factor receptor (EGFR), with downstream activation of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways (Kahlenberg and Kaplan, 2013).
3.3 Chemotactic Activity
A pivotal finding in the characterisation of LL-37 as an immunomodulatory molecule was the demonstration by Yang et al. (2000) that the peptide functions as a chemoattractant for human peripheral blood neutrophils, monocytes, and T lymphocytes. Using Boyden chamber chemotaxis assays, the investigators established that LL-37 induces directed migration of these immune cell populations at nanomolar concentrations, with the chemotactic activity mediated through FPRL1 (now designated FPR2). This receptor belongs to the formyl peptide receptor family, a group of G protein-coupled receptors that detect microbial and host-derived danger signals and play established roles in inflammatory cell trafficking (Yang et al., 2000). The chemotactic activity of LL-37 provides a mechanism by which local production of the peptide at sites of infection or tissue injury can amplify innate immune responses by recruiting effector cells from the circulation.
4. Antimicrobial Research
LL-37 exhibits broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, certain fungi, and enveloped viruses. In vitro studies have demonstrated bactericidal activity against clinically relevant pathogens including Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Streptococcus species, with minimum inhibitory concentrations typically in the low micromolar range (Dürr, Sudheendra and Ramamoorthy, 2006). Of particular interest is the activity of LL-37 against antibiotic-resistant organisms, including methicillin-resistant S. aureus (MRSA), where the membrane-disruptive mechanism of action circumvents the resistance mechanisms that render beta-lactam antibiotics ineffective (Hancock and Sahl, 2006).
The anti-biofilm activity of LL-37 represents a distinct and therapeutically relevant aspect of its antimicrobial profile. Overhage et al. (2008) demonstrated that LL-37 inhibits Pseudomonas aeruginosa biofilm formation at concentrations well below its minimum inhibitory concentration for planktonic bacteria. The peptide was shown to impair initial bacterial attachment, stimulate twitching motility that counteracts the sessile biofilm phenotype, and downregulate genes essential for biofilm development, including those involved in quorum sensing and type IV pilus biogenesis (Overhage et al., 2008). Given that biofilm-associated infections are notoriously refractory to conventional antibiotic therapy, the capacity of LL-37 to disrupt biofilm formation at sub-bactericidal concentrations has attracted considerable research attention as a potential strategy for addressing chronic and device-associated infections.
5. Wound Healing Research
The involvement of LL-37 in cutaneous wound repair was substantively established by Heilborn et al. (2003), who demonstrated that the peptide is markedly upregulated in human skin wounds during the inflammatory and early proliferative phases of healing. Using immunohistochemistry and in situ hybridisation, the investigators showed that hCAP-18/LL-37 expression was strongly induced in keratinocytes at the wound margin, with peak expression occurring during the period of active re-epithelialisation. Critically, the study also revealed that LL-37 expression was conspicuously absent from the epithelium of chronic, non-healing ulcers, suggesting a functional role for the peptide in successful wound closure (Heilborn et al., 2003).
Subsequent functional studies have elucidated several mechanisms through which LL-37 may promote wound healing. The peptide stimulates keratinocyte and fibroblast proliferation and migration through transactivation of the epidermal growth factor receptor (EGFR) and downstream MAPK/ERK signalling. LL-37 has additionally been shown to promote angiogenesis by stimulating endothelial cell proliferation and formation of vessel-like tubular structures in vitro, an effect attributed to activation of FPR2 and EGFR-dependent pathways (Vandamme et al., 2012). The combination of antimicrobial protection, immune cell recruitment, epithelial cell stimulation, and pro-angiogenic activity positions LL-37 as a multifunctional mediator that coordinates several key processes required for effective tissue repair.
6. Role in Innate Immunity
LL-37 occupies a central position within the innate immune system as both a direct antimicrobial effector and a signalling molecule that bridges innate and adaptive immune responses. The peptide is released from neutrophil specific granules upon degranulation at sites of infection, where it contributes to microbial killing within the phagolysosome and in the extracellular space. At epithelial surfaces, inducible expression of LL-37 provides a chemical barrier that complements the physical barrier function of the epithelium (Zanetti, 2004).
The capacity of LL-37 to neutralise bacterial endotoxin (LPS) represents a particularly important immunological function. By binding directly to LPS, LL-37 prevents the formation of the LPS-LBP-CD14-TLR4 signalling complex, thereby attenuating the excessive pro-inflammatory cytokine release that characterises endotoxaemia and septic shock. This anti-endotoxin activity, combined with the peptide's direct bactericidal effects, positions LL-37 as a dual-function molecule capable of simultaneously eliminating pathogens and limiting the collateral tissue damage caused by uncontrolled inflammatory responses to microbial products (Scott et al., 2002).
Furthermore, LL-37 has been implicated in the activation of dendritic cells and the enhancement of antigen presentation, suggesting a role in shaping downstream adaptive immune responses. The peptide facilitates the uptake of self-DNA and self-RNA by plasmacytoid dendritic cells, forming complexes that activate TLR9 and TLR7/8 respectively. While this mechanism has physiological relevance in antimicrobial defence, it has also been implicated in the pathogenesis of psoriasis and systemic lupus erythematosus, where aberrant LL-37-nucleic acid complex formation may drive inappropriate type I interferon production (Kahlenberg and Kaplan, 2013).
7. Current Research Directions and Limitations
Contemporary research on LL-37 encompasses several active areas of investigation. The development of synthetic analogues and truncated derivatives with enhanced antimicrobial potency, improved stability, and reduced cytotoxicity represents a major thrust of medicinal chemistry efforts. Structure-activity relationship studies have identified shorter fragments of LL-37, such as the central helical segment comprising residues 17-29 (designated FK-16 or KR-12 depending on the fragment boundaries), that retain antimicrobial activity while potentially offering improved therapeutic indices (Wang, 2014).
The anti-biofilm properties of LL-37 and its derivatives continue to attract substantial research interest, particularly in the context of implant-associated infections and chronic wound biofilms. Surface coating strategies that incorporate LL-37 or its analogues onto medical device surfaces are under investigation as a means of preventing bacterial colonisation and biofilm formation on prosthetic joints, catheters, and wound dressings (Overhage et al., 2008). Additionally, the immunomodulatory properties of LL-37 have prompted exploration of the peptide as an adjuvant in vaccine formulations, where its capacity to activate dendritic cells and promote chemotaxis of antigen-presenting cells could enhance adaptive immune responses to co-administered antigens (Hancock and Sahl, 2006).
Several important limitations of the current evidence base warrant consideration. The antimicrobial activity of LL-37 is significantly attenuated in the presence of physiological salt concentrations and serum proteins, raising questions about the effective concentrations achieved at sites of infection in vivo. The majority of mechanistic studies have been conducted using synthetic LL-37 in cell culture or animal models, and the translation of these findings to human clinical applications remains at an early stage. Pharmacokinetic challenges, including susceptibility to proteolytic degradation and the potential for cytotoxicity at elevated concentrations, represent practical barriers to the development of LL-37 as a therapeutic agent (Vandamme et al., 2012).
In summary, LL-37 represents the sole human cathelicidin antimicrobial peptide and functions as a multifaceted effector of innate immunity. Its biological activities encompass direct membrane-disruptive antimicrobial killing, anti-biofilm effects, endotoxin neutralisation, chemotactic recruitment of immune cells, immunomodulatory signalling through multiple receptor systems, and promotion of wound healing processes including re-epithelialisation and angiogenesis. These diverse functions, mediated by a single endogenous peptide, underscore the sophistication of innate immune defence mechanisms and have established LL-37 as a compound of considerable interest across antimicrobial, immunological, and wound healing research. The advancement of this research towards clinical applications will require resolution of pharmacokinetic limitations, development of optimised synthetic analogues, and generation of controlled clinical trial data in relevant patient populations.